ALKEM LABORATORIES LTD Q2 RESULTS
InCred cuts Nifty50 blended index target to 25,327, upgrades pharma to overweight
InCred Equities cut Nifty50 target to 25,327, expecting a correction phase. The brokerage upgraded its stance on pharma stocks like Cipla, Ipca, and Alkem Laboratories. The IT, capital goods, and pharma sectors outperformed during the recent correction. The overall market sentiment remains cautious due to weak macroeconomic conditions and potential EPS downgrades.
Election outcome, MSCI rejig among 8 factors to likely impact stock markets this week
Nifty closed Friday with a 1.6% weekly gain, boosted by strong bank and IT stocks. On Friday, it ended at 23,907.25, up by 2.39%. As markets reopen on Monday, key domestic and global events are expected to influence movements.
Add Alkem Laboratories, target price Rs 6,180: HDFC Securities
HDFC Securities recommends buying shares of Alkem Laboratories. They set a target price of Rs 6,180. The current market price is Rs 5,535. Alkem Laboratories' recent performance was slightly below expectations. However, the company expects growth in the Indian pharmaceutical market and improved profitability. HDFC Securities believes Alkem Laboratories will experience steady growth in the coming years.
Ipca Labs Q2 Results: Profit shoots up 58% to Rs 229 crore
Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period.
Alkem Labs Q2 Results: Net profit rises 11% to Rs 689 crore
Alkem Laboratories on Wednesday posted a 11% year-on-year (y-o-y) jump in net profit to Rs 689 crore in Q2FY25 led by growth in domestic formulation sales.
Q2 results this week: Hyundai, Nykaa, Vodafone Idea among 2515 companies to announce earnings
Over 2500 companies, including prominent names like ONGC, Hindalco, and Hero MotoCorp, are set to release their second-quarter earnings this week. Early reports suggest muted results, with analysts predicting the slowest growth in over four years due to a marginal 2% rise in Nifty earnings.
- Go To Page 1
Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25
Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis business. This growth was driven by increased demand from new and existing customers seeking supply chain diversification beyond China.
Divi's Laboratories Q2 Results: PAT jumps 46% YoY to Rs 510 crore on forex gain
Divi's Laboratories Q2 Results: The company reported a 22.5% year-on-year revenue increase in Q2, reaching Rs 2,338 crore, up from Rs 1,909 crore in the previous year’s corresponding quarter. Profit before tax rose to Rs 722 crore, compared to Rs 469 crore in the same period last year.
Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%
Dr Reddy's Labs Q2 Results: Healthcare major Dr Reddy's on Tuesday reported 15% drop in its consolidated net profit at Rs 1255 crore in the second quarter. It was Rs 1480 crore in the year-ago quarter.
Q2 results this week: Tata Motors, Tata Steel, M&M, Trent, SBI among 170 companies to announce earnings
The second quarter earnings season is underway and as many as 170 companies will declare their results this week. Some of the marquee names include Titan, Asian Paints, PB Fintech, IRCTC, IRFC, RVNL, Mazagon Dock Ship, Tata Steel, Mahindra & Mahindra, Trent, LIC, MRF, Tata Motors, and SBI among others.
US election, Q2 earnings, Fed meet and 5 more factors to likely impact stock markets this week
"The domestic market showed positive reversal signs this week, aided by festive sentiment, steady institutional inflows, and declining oil prices," said Vinod Nair, Head of Research at Geojit Financial Services. Market sentiment was also uplifted by easing geopolitical tensions and positive India-China relations.
For medium-term investors: Even in times of correction, ignoring mid-caps is not an option; being selective was, is, and will remain a necessity
Fifteen years back, a company from a large industrial house raised money by floating corporate bonds at X% interest. A mid-size company raised money at X% plus 200 basis points. It was thus paying 2% more for the capital, putting it at a disadvantage. Today, that large company is raising money at X% – but so is the mid-sized company. The reason: Capital is now more easily available, and the company has also improved its balance sheet. For all mid-caps it is the cost of capital that is key. Now, whether the Nifty moves up or down, the trajectory of interest rates is surely headed south this month.
Cipla Q2 hit by seasonal chill, but investors need not worry
Cipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal growth in the anti-infectives category. The company expects a resurgence in growth due to seasonal respiratory illnesses and plans to address supply challenges and facility remediations in upcoming quarters.
Dr. Reddy’s shares trade ex-split today. Stock up 2%
The company further announced that each American Depositary Share (ADS) will continue to represent one equity share. Consequently, the number of ADSs held by each American Depositary Receipt holder will increase in line with the rise in equity shares.
Dr Reddy's Laboratories, TCS top stocks to buy post June quarter results: Siddhartha Khemka
The 1QFY25 corporate earnings report revealed both growth and challenges in India’s market. The Nifty50’s earnings rose 4% YoY, aided by companies like HDFC Bank and Tata Motors, despite setbacks from Oil Marketing Companies. The auto sector displayed strong volume growth, while IT services and healthcare sectors met expectations with promising future outlooks.
Ipca Labs Q1 Results: Net profit up 18% at Rs 192 crore
Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Move over PSUs, defensive bets can be the next big story under Modi 3.0
Defensive sectors like FMCG and pharma are emerging as potential winners under Modi 3.0, with experts forecasting gains fueled by rural push and policy actions. Investors are advised to explore stocks like HUL, Dabur, and pharma majors for potential returns amidst PSU valuation concerns.
Divi’s Laboratories shares rally 5% post Q4 results. Should you buy, sell or hold?
Divi’s Laboratories saw a 5% surge in its shares on the BSE during Monday's trading session, reaching a new 52-week high of Rs 4,335. This rise came as brokerages such as Motilal Oswal and InCred expressed bullish sentiment towards the stock, following the company's impressive performance in Q4, where it reported a 68% year-on-year increase in profits, reaching Rs 538 crore.
Divi's Laboratories Q4 Results: Cons PAT soars 68% YoY to Rs 538 crore; dividend declared at Rs 30 per share
Divi's Laboratories Q4 Results: Net profit stood at Rs 321 crore in the corresponding quarter of the last financial year. The consolidated revenue in Q4 FY24 jumped 18% YoY to Rs 2,303 crore from Rs 1,951 crore reported in Q4 FY23. For the full financial year FY24, the consolidated profit after tax was reported at Rs 1,600 crore, a considerable drop from Rs 1,824 crore reported in FY23.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Abbott India Q4 Results: Net profit rises 24% YoY on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Alkem Laboratories Q2 net profit up 76% at Rs 614.89 cr
Alkem Laboratories Ltd on Tuesday reported a 76.83% rise in consolidated net profit at Rs 614.89 crore for the second quarter ended September 30, on the back of lower raw material cost and lower intensity of price erosion in the US market. Total expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the company said.
Alkem Laboratories Q2 Results: Net profit up 77% YoY at Rs 615 crore
Total expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the company said.
Load More
